Cited 9 times in
Influence of Insurance Benefit Criteria on the Administration Rate of Osteoporosis Drugs in Postmenopausal Females
DC Field | Value | Language |
---|---|---|
dc.contributor.author | 문성환 | - |
dc.date.accessioned | 2015-01-06T16:39:09Z | - |
dc.date.available | 2015-01-06T16:39:09Z | - |
dc.date.issued | 2014 | - |
dc.identifier.issn | 2005-291X | - |
dc.identifier.uri | https://ir.ymlib.yonsei.ac.kr/handle/22282913/98504 | - |
dc.description.abstract | BACKGROUND: Preventive measures need to be implemented to lower the incidence of osteoporotic fractures. Osteoporotic fractures increase morbidity and mortality as well as impose a socioeconomic burden; however, current research is limited to the administration rates of osteoporosis drugs for Korean postmenopausal females. METHODS: This study represents a nationwide, observational, and cross-sectional survey that investigates the administration rates of osteoporosis drugs based upon a bone mineral density (BMD) test performed on Korean postmenopausal patients who visited outpatient orthopedic clinics. BMD test results were examined in postmenopausal female patients (50 to 80 years of age); subsequently, the patients were classified into an osteoporosis group, osteopenia group, and normal group. The administration rates of osteoporosis drugs and bisphosphonates were then analyzed. The osteoporosis group was subdivided into a T-score less than -3.0 group and a T-score between -3.0 and -2.5 group that were separately analyzed. RESULTS: Based on the lumbar spine BMD, the rate of administration of osteoporosis drugs in the osteoporosis group was 42.1%, which was significantly higher compared to the osteopenia group or normal group. A significantly low bone mineral density was observed in patients who were administered bisphosphonates. Based on the lumbar spine BMD, the administration rate of osteoporosis drugs in the group with a T-score between -3.0 and -2.5 (34.2%) was significantly lower than the group with a T-score less that -3.0 (46.2%). The bisphosphonate administration rate was also significantly low; however, the administration rate for osteoporosis drugs was significantly lower than that of the osteopenia group. CONCLUSIONS: Only about 40% of Korean postmenopausal female patients with osteoporosis were administered osteoporosis drugs. The administration rate in patients with a T-score between -3.0 and -2.5 was particularly low and active treatment to prevent osteoporotic fractures is required in this group. | - |
dc.description.statementOfResponsibility | open | - |
dc.format.extent | 56~61 | - |
dc.language | English | - |
dc.publisher | Korean Orthopaedic Association | - |
dc.relation.isPartOf | CLINICS IN ORTHOPEDIC SURGERY | - |
dc.rights | CC BY-NC-ND 2.0 KR | - |
dc.rights.uri | https://creativecommons.org/licenses/by-nc-nd/2.0/kr/ | - |
dc.subject.MESH | Aged | - |
dc.subject.MESH | Aged, 80 and over | - |
dc.subject.MESH | Bone Density Conservation Agents/therapeutic use* | - |
dc.subject.MESH | Cross-Sectional Studies | - |
dc.subject.MESH | Drug Prescriptions/statistics & numerical data* | - |
dc.subject.MESH | Female | - |
dc.subject.MESH | Humans | - |
dc.subject.MESH | Insurance Benefits/methods* | - |
dc.subject.MESH | Middle Aged | - |
dc.subject.MESH | Osteoporosis/drug therapy* | - |
dc.subject.MESH | Osteoporosis/epidemiology | - |
dc.subject.MESH | Republic of Korea | - |
dc.title | Influence of Insurance Benefit Criteria on the Administration Rate of Osteoporosis Drugs in Postmenopausal Females | - |
dc.type | Article | - |
dc.contributor.college | College of Medicine (의과대학) | - |
dc.contributor.department | Dept. of Orthopedic Surgery (정형외과학) | - |
dc.contributor.googleauthor | Jae Hyup Lee | - |
dc.contributor.googleauthor | Ye-Hyun Lee | - |
dc.contributor.googleauthor | Seoung-Hwan Moon | - |
dc.contributor.googleauthor | Yil-Seob Lee | - |
dc.identifier.doi | 10.4055/cios.2014.6.1.56 | - |
dc.admin.author | false | - |
dc.admin.mapping | false | - |
dc.contributor.localId | A01365 | - |
dc.relation.journalcode | J00620 | - |
dc.identifier.eissn | 2005-4408 | - |
dc.identifier.pmid | 24605190 | - |
dc.subject.keyword | Bisphophonate | - |
dc.subject.keyword | Korean | - |
dc.subject.keyword | National Health Insurance Service | - |
dc.subject.keyword | Osteoporosis medication | - |
dc.subject.keyword | Postmenopausal osteoporosis | - |
dc.contributor.alternativeName | Moon, Seong Hwan | - |
dc.contributor.affiliatedAuthor | Moon, Seong Hwan | - |
dc.citation.volume | 6 | - |
dc.citation.number | 1 | - |
dc.citation.startPage | 56 | - |
dc.citation.endPage | 61 | - |
dc.identifier.bibliographicCitation | CLINICS IN ORTHOPEDIC SURGERY, Vol.6(1) : 56-61, 2014 | - |
dc.identifier.rimsid | 57631 | - |
dc.type.rims | ART | - |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.